Micromet to Present Updates on Clinical Trials with Blinatumomab at Annual Meeting of American Society of Hematology
30 November 2009 - 11:00PM
PR Newswire (US)
BETHESDA, Md., Nov. 30 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that it will present new
results from its clinical studies with blinatumomab at the 51st
annual meeting of the American Society of Hematology from December
5-8, 2009 in New Orleans, Louisiana. Results from the completed
phase 2 clinical trial with blinatumomab in patients with acute
lymphoblastic leukemia (ALL) were chosen for an oral presentation.
An update from the ongoing phase 1 trial with blinatumomab in
patients with non-Hodgkin's lymphoma (NHL) will be presented in a
poster. (1) Topp et al, (2009) Report of a phase II trial of
single-agent BiTE antibody blinatumomab in patients with minimal
residual disease (MRD) positive B-precursor acute lymphoblastic
leukemia (ALL): 51st ASH meeting (2009), abstract number 840; oral
presentation on December 8 in rooms 220-222 at 8:45 AM. (2)
Nagorsen, et al. (2009) Confirmation of safety, efficacy and
response duration in non-Hodgkin lymphoma patients treated with 60
micrograms/squaremeter per day of BiTE antibody blinatumomab. 51st
AST meeting (2009), abstract number 2723; to be presented in poster
presentation on December 6, 2009, 6:00 PM. For more information and
for complete abstracts, please visit
http://ash.confex.com/ash/2009/webprogram/start.html About BiTE
Antibodies BiTEĀ® antibodies are designed to direct the body's
cytotoxic, or cell-destroying, T cells against tumor cells, and
represent a new therapeutic approach to cancer therapy. Typically,
antibodies cannot engage T cells because T cells lack the
appropriate receptors for binding antibodies. BiTE antibodies have
been shown to bind T cells to tumor cells, ultimately inducing a
self-destruction process in the tumor cells referred to as
apoptosis, or programmed cell death. In the presence of BiTE
antibodies, T cells have been demonstrated to serially eliminate
tumor cells, which explains the activity of BiTE antibodies at very
low concentrations. Through the killing process, T cells start to
proliferate, which leads to an increased number of T cells at the
site of attack. About Micromet, Inc. Micromet, Inc. is a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases.
Its product development pipeline includes novel antibodies
generated with its proprietary BiTEĀ® antibody platform, as well as
conventional monoclonal antibodies. Two of Micromet's BiTE
antibodies and three of its conventional antibodies are currently
in clinical trials. Micromet's preclinical product pipeline
includes several novel BiTE antibodies generated with its
proprietary BiTE antibody platform technology. Micromet's
collaboration partners include sanofi-aventis, Bayer Schering
Pharma, Merck Serono, MedImmune and Nycomed. Forward-Looking
Statements This release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. These forward-looking statements include statements
regarding the development and commercialization of blinatumomab,
including the conduct and timing of future clinical trials
involving this product candidate. You are urged to consider
statements that include the words "ongoing," "may," "will,"
"believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
blinatumomab does not demonstrate safety and/or efficacy in future
clinical trials, the risk that we will not obtain approval to
market blinatumomab and the risks associated with reliance on
outside financing to meet capital requirements. These factors and
others are more fully discussed in Micromet's Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2009, filed
with the SEC on November 6, 2009, as well as other filings by the
company with the SEC. DATASOURCE: Micromet, Inc. CONTACT: US Media:
Chris Stamm, +1-781-684-0770, ; US Investors: Susan Noonan,
+1-212-966-3650, ; European Media: Ludger Wess, +49 (40) 8816 5964,
; or European Investors: Ines-Regina Buth, +49 (30) 2363 2768, Web
Site: http://www.micromet-inc.com/
Copyright